Why Use HepatoPac
Contact Ascendance-Hepregen

Why Use HepatoPac®

The Problem

As many as 30% of compounds never reach the market because of liver metabolism and toxicity issues. Additionally, liver toxicity is a main reason drugs are recalled from pharmacy shelves post product introduction. Why such a high attrition rate?

  • Traditional in vitro methods use short-lived primary hepatocyte cultures that are not stable enough to predict long-term effects on the liver
  • Animal studies cannot duplicate the human liver's functional behavior

The Solution

Licensed from MIT, the HepatoPac platform addresses these issues by providing a highly functional and stable culture that mimics the human liver.

  • HepatoPac demonstrates physiologically relevant metabolic activity including Phase I, Phase II, and Transporter activity for over four weeks
  • HepatoPac has been proven to work in many real-world examples and provides improved IVIVC over standard in vitro liver models
  • HepatoPac is available in multiple species and flexible plate formats
  • HepatoPac is validated for a broad range of ADME/Tox applications

Organizational Drug-Development Pipeline

If not discovered, hepatotoxic compounds advance through clinical trials, resulting in misappropriated time and money. HepatoPac improves the likelihood of identifying hepatotoxicity by 30% during the pre-clinical phase - a cost-effective solution that focuses your company's efforts on improved drug candidates and ultimately saves  millions of dollars.

Organizational Drug-Development Pipeline
Click to enlarge

Application Flexibility

  • Primary, secondary and tertiary metabolite identification (Met ID)
  • Metabolite stability
  • Multi-dose or chronic toxicity testing
  • Low turnover compound analysis
  • Transporter Assays
  • Predictive and Mechanistic Toxicity
  • Drug-drug interactions (DDI)
  • Drug-induced liver injury (DILI)

Technical Resources

Type Title
Application Note HepatoPac® A Bioengineered Micro-Liver Platform for Predictive Drug Metabolism and Toxicity Studies. A Predictive, In Vitro Micro-Liver Co-culture System Providing In Vivo Performance
Case Study Ability of a Micropatterned Hepatocyte Co-culture System to Generate Major Human Drug Metabolites.
Publication Bridging in vitro and in vivo metabolism and transport of faldaprevir in humans using a novel cocultured human hepatocyte system, HepatoPac®. Drug Metab and Dispos . Early Access. December 2013.
Publication Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac® Drug Metab and Dispos. Vol. 41(12), p 2024-2032 (2013).
Publication Bioactivation and Toxicity of Acetaminophen in a Rat Hepatocyte Micropatterned Coculture System. Journal of Biochemical and Molecular Toxicology. Early Release Epub, August 5, 2013.
Publication The Use of Micropatterned Co-Cultures to Detect Compounds that Cause Drug induced Liver Injury in Humans. Toxicol. Sci. 132 (1): p 107-117, (2013).
Publication Microscale culture of human liver cells for drug development. Nat Biotechnol, 26(1), 120-126 (2007).